

R&D Costs			
Year	R&D (billions DKK)	R&D (billions USD)	
2024 Q2	16.166	2.319036006	
2024 Q1	8.606	1.244720856	
2023	32.443	4.708708273	
2022	24.047	3.397908718	
2021	17.772	2.825437202	
2020	15.462	2.364943408	
2019	14.22	2.131934033	
2018	14.805	2.342934009	
Sum	143.521	21.3356225	
Stock Buybacks			
Year	Treasury Repurchase (billio	Treasury Repurchase (billions USD)	
2024 H1	10.285	1.481454807	
2023	29.924	4.343105951	
2022	24.086	3.403419528	
2021	19.447	3.091732909	
2020	16.855	2.578005506	
2019	15.334	2.298950525	
2018	15.567	2.463522709	
Sum	131.498	19.66019194	
Dividends paid			
Year	Divdends (billions DKK)	Divdends (billions USD)	
2024 H1	28.557	4.113359741	
2023	31.767	4.610595065	
2022	25.303	3.57538505	
2021	21.517	3.420826709	
2020	20.121	3.07754665	
2019	19.409	2.909895052	
2018	19.048	3.014401013	
Sum	165.722	24.72200928	
Total Stock Buybacks+Dividends (2018-2024Q2)		44.38220122	

Ozempic Revenue		
Year	Revenue (billions DKK)	Revenue (billions USD)
2024 Q2	28.875	4.142160379
2024 Q1	27.81	4.022273648
2023	95.7	13.88969521
2022	59.8	8.449908153
2021	33.7	5.357710652
2020	21.2	3.242581829
2019	11.2	1.67916042
2018	1.796	0.284222187
Sum	280.081	41.06771248
Wegovy Revenue		
Year	Revenue (billions DKK)	Revenue (billions USD)
2024 Q2	11.659	1.672500359
2024 Q1	9.377	1.356233729
2023	31.343	4.549056604
2022	6.188	0.8743818
2021	1.386	0.220349762
Sum	59.953	8.672522253
	Total Ozempic, Wegovy (2018-2024Q2)	
		49.74023473
	Total Ozempic, Wegovy 2024 H1	
		11.19316811

Sources								
2024 Q1, Q2	https://www.novonordisk.com/investors/financial-results.html							
2023 Annual Report	https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual_report/2024/novo-nordisk-annual-report-2023.pdf							
2023 Form 20-F	https://www.sec.gov/ix?doc=/Archives/edgar/data/0000353278/000162828024002635/nvo-20231231.htm							
2022 Form 20-F	https://www.sec.gov/ix?doc=/Archives/edgar/data/0000353278/000162828023001868/nvo-20221231.htm							
2021 Form 20-F	https://www.sec.gov/ix?doc=/Archives/edgar/data/0000353278/000162828022001639/nvo-20211231.htm							
2020 Form 20-F	https://www.sec.gov/Archives/edgar/data/353278/000162828021001364/novo-b20xf12x31x20.htm							
2019 Form 20-F	https://www.sec.gov/Archives/edgar/data/353278/000162828020001021/novo-b20xf12x31x19.htm							
2018 Form 20-F	https://www.sec.gov/Archives/edgar/data/353278/000162828019000875/novo-b20xf12x31x18.htm							
2023-2021 R&D, 20-F Filing for 20	https://www.sec.gov/Archives/edgar/data/353278/000162828024002635/nvo-20231231_d2.htm							
2020-2018 R&D, 20-F Filing for 20	https://www.sec.gov/ix?doc=/Archives/edgar/data/353278/000162828021001358/nvo-20201231.htm							